Aspiriant LLC’s Dimensional US Marketwide Value ETF DFUV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.3M Sell
708,215
-9,884
-1% -$485K 0.98% 16
2025
Q4
$33.5M Sell
718,099
-6,994
-1% -$317K 0.96% 17
2025
Q3
$32.4M Buy
725,093
+4,480
+0.6% +$195K 0.99% 16
2025
Q2
$30.5M Buy
720,613
+18,118
+3% +$728K 0.97% 17
2025
Q1
$28.9M Buy
702,495
+6,603
+0.9% +$277K 1% 15
2024
Q4
$28.5M Sell
695,892
-2,394
-0.3% -$102K 1.03% 15
2024
Q3
$29.1M Sell
698,286
-11,452
-2% -$463K 1.1% 15
2024
Q2
$27.9M Buy
709,738
+639
+0.1% +$25.3K 1.14% 14
2024
Q1
$29M Sell
709,099
-2,480
-0.3% -$94.7K 1.2% 15
2023
Q4
$26.5M Sell
711,579
-12,362
-2% -$426K 1.19% 13
2023
Q3
$24.6M Buy
723,941
+29,196
+4% +$1.02M 1.26% 16
2023
Q2
$24M Sell
694,745
-4,446
-0.6% -$149K 1.21% 16
2023
Q1
$23.4M Sell
699,191
-9,775
-1% -$335K 1.23% 16
2022
Q4
$23.7M Sell
708,966
-29,993
-4% -$997K 1.21% 16
2022
Q3
$21.9M Sell
738,959
-6,935
-0.9% -$226K 1.07% 22
2022
Q2
$23.6M Buy
+745,894
New +$24.8M 1.14% 18

Other funds holding DFUV

Aspiriant LLC's DFUV Position: Q1 2026 in Review

Aspiriant LLC reduced its Dimensional US Marketwide Value ETF (DFUV) stake by 1.4% in Q1 2026, selling an estimated $485K and leaving 708,215 shares worth $34.3M. The position accounts for 0.98% of the portfolio, ranked #16.

Aspiriant LLC first reported a position in DFUV in Q2 2022 and has held it in 16 quarters since. 766 funds tracked by Wall St. Rank hold DFUV as of Q1 2026.

  • Aspiriant LLC held 708,215 shares of Dimensional US Marketwide Value ETF worth $34.3M as of Q1 2026.
  • Aspiriant LLC sold 9,884 Dimensional US Marketwide Value ETF shares in Q1 2026, an estimated $485K.
  • Dimensional US Marketwide Value ETF made up 0.98% of Aspiriant LLC's portfolio in Q1 2026, its #16 holding.
  • Aspiriant LLC first reported a position in Dimensional US Marketwide Value ETF in Q2 2022 and has held it in 16 quarters since.
  • 766 funds tracked by Wall St. Rank held Dimensional US Marketwide Value ETF as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.